Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Small Molecule FASN Inhibitors Demonstrate Antiviral Activity

MENLO PARK, Calif., Nov. 10, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9-13 in Boston, Massachusetts. 

(Logo:  http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"New, potent therapeutics that combine with and improve on the evolving standard of care for the treatment of hepatitis C infection are needed to ensure that we can reach the broadest population of patients with appropriate, curative regimens," said George Kemble, Chief Scientific Officer of 3-V Biosciences.  "3-V's FASN inhibitors represent an entirely new class of therapy.  With a novel mechanism of action, and broad-spectrum, potent antiviral activity demonstrated across multiple preclinical studies, we believe that our FASN inhibitors will bring substantial benefits to patients as a key component in emerging multi-drug treatment regimens.  We look forward to initiating clinical studies early next year."

Novel FASN Inhibitors
3-V's FASN inhibitors for the treatment of HCV are designed to have broad-spectrum activity, a high barrier to resistance and the ability to combine with direct-acting antivirals, such as nucleotide/nucleoside inhibitors, protease inhibitors, NS5a inhibitors and other mechanisms of action currently in development.  Data characterizing the preclinical antiviral activity of 3-V's FASN inhibitors will be featured in oral and poster presentations during The Liver Meeting.  Highlights of these data include:

  • Orally bioavailable representative molecules are potent and specific, with IC50s in the 5-50nM range;
  • Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN;
  • Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and
  • Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors.

3-V's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties.  The company has filed multiple worldwide patent applications covering these inhibitors.  3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

Data describing 3-V's FASN inhibitor preclinical activity will be presented by Dr. Kemble during Sunday's HCV Therapy: Preclinical and Early Clinical Development parallel session at 5:30 pm in a talk titled: "Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase" (Abstract #88).  A poster, "TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition in Vivo" (Abstract #1876), describing mechanism and activity for one of 3-V's compounds will be presented on Tuesday, November 13 during the HCV Therapy: Preclinical and Early Clinical Development poster session from 8:00 a.m. to 12:00 p.m.

About FASN
FASN is a cellular enzyme implicated in HCV replication and several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and have the potential to become significant new approaches to the treatment of chronic HCV and other indications.

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Stephen R. Brady
Chief Business Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com

Michelle Corral
415-794-8662
mcorral@bccpartners.com

SOURCE 3-V Biosciences, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
You can then easily piece together full transaction traces by ordering all method calls by sequence number. Further analysis can be applied to this information for a number of purposes. For example, by analysing the transactions, developers can easily construct design diagrams that can...
Every day and every second, the system administrator gets tones of information on the network operation, network devices’ operation, and messages from users; he sets dozens of challenges, which must help to avoid the existing and possible problems in the future. Often, it is rather dif...
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is ob...
With the increasing complexity of software, organizations are more cognizant than ever about the potential pitfalls of including open source code in their products. Below are some quick tips to continue leveraging open source code, while keeping your manager and legal department happy.
The industry is heated with debates on whether adopting private or public cloud is the smartest, best, cheapest, you name it choice. But this debate is missing the mark. Businesses shouldn’t be discussing public vs. private, but rather how can they make the two work together to their g...
In his session at 15th Cloud Expo, Mark Hinkle, Senior Director, Open Source Solutions at Citrix Systems Inc., will provide overview of the open source software that can be used to deploy and manage a cloud computing environment. He will include information on storage, networking(e.g.,...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE